Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Asia Playing A More Important Role In Global Clinical Trials: World Pharma Trials Asia

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - With big pharmaceutical firms increasing their focus on emerging markets, more and more trials are now being conducted across Asia, including China, India, Turkey and South Korea, speakers at World Pharma Trials Asia 2010 said Sept. 14 in Shanghai

You may also be interested in...



Takeda Takes Global Expansion Next Door To South Korea

TOKYO - Takeda, Japan's largest drug manufacturer by sales, made an announcement June 23 that may come as a surprise. This year, the company hopes to establish its own commercial presence in South Korea, one of Japan's closest neighbors and one of Asia's largest markets

More Talks Needed With China and Japan For Cooperation In Sharing Clinical Data - Korea FDA Official

SEOUL - Although drug regulatory officials from South Korea, Japan and China met in Beijing for two days from Dec. 17 in their second tri-party meeting, they failed to report "noticeable progress" in their pursuit of an integrated clinical trial data-sharing program and mutual acceptance of their rules and guidelines, according to Korea FDA

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

SC075922

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel